Trial
NCT03238703
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
HER2/Neu Negative
Intervention
Anastrozole
Why stopped
Administrative closure based on sponsor recommendation, prior to subject enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-12-27